Analytical Development, Biogen Idec, Cambridge, Massachusetts 02142, USA.
J Pharm Sci. 2012 May;101(5):1688-700. doi: 10.1002/jps.23064. Epub 2012 Jan 23.
A long lasting recombinant factor IX -Fc fusion protein (rFIX-Fc) is being developed for the treatment of hemophilia B and is currently in late stage clinical investigation. By limiting injection frequency and maintaining efficacy, rFIX-Fc shows promise as a new therapeutic option for hemophilia B patients. However, before gaining regulatory approval, rFIX-Fc must undergo rigorous analytical and biological testing, in addition to clinical trials. Included in this testing is the need to understand this protein's higher-order structure and dynamics. In this study, we investigated and compared the biophysical properties of rFIX-Fc, rFIX, and Fc using hydrogen/deuterium exchange mass spectrometry and differential scanning calorimetry. Within the limits of these techniques, our results show that structural comparability exists between rFIX and the FIX region of rFIX-Fc. In addition, changes in the structure and dynamics of both proteins, in response to calcium binding, a requirement for FIX function, are also highly comparable. In the case of Fc and Fc region of rFIX-Fc, conformational comparability is also established. These biophysical results further support the conclusion that fusing an immunoglobulin gamma 1 Fc to rFIX does not significantly alter the higher-order structure of FIX or Fc, Ca binding to FIX, or Fc functionality.
一种长效的重组因子 IX-Fc 融合蛋白(rFIX-Fc)正在被开发用于治疗乙型血友病,目前处于临床研究后期。通过限制注射频率并保持疗效,rFIX-Fc 有望成为乙型血友病患者的一种新的治疗选择。然而,在获得监管批准之前,rFIX-Fc 必须经过严格的分析和生物学测试,以及临床试验。其中包括需要了解该蛋白质的高级结构和动力学。在这项研究中,我们使用氢/氘交换质谱和差示扫描量热法研究和比较了 rFIX-Fc、rFIX 和 Fc 的生物物理特性。在这些技术的限制范围内,我们的结果表明,rFIX 和 rFIX-Fc 的 FIX 区域之间存在结构可比性。此外,两种蛋白质的结构和动力学变化对钙结合的反应,这是 FIX 功能的要求,也高度可比。对于 Fc 和 rFIX-Fc 的 Fc 区域,也建立了构象可比性。这些生物物理结果进一步支持了这样的结论,即融合免疫球蛋白 γ1 Fc 到 rFIX 不会显著改变 FIX 或 Fc 的高级结构、FIX 与钙的结合,或 Fc 的功能。